Baijin Life Science Holdings (OTCPK:MNNGF) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Baijin Life Science Holdings EBITDA Margin % Related Terms
Baijin Life Science Holdings EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Baijin Life Science Holdings EBITDA Margin % Chart
For the Luxury Goods subindustry, Baijin Life Science Holdings's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Baijin Life Science Holdings EBITDA Margin % vs Retail - Cyclical Industry
For the Retail - Cyclical industry and Consumer Cyclical sector, Baijin Life Science Holdings's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Baijin Life Science Holdings's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Baijin Life Science Holdings (MNNGF) has a EBITDA Margin % of 11.79% as of Sep. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Baijin Life Science Holdings and its competitors. According to the industry distribution chart, Baijin Life Science Holdings ranks #617 out of 1128 companies in the Retail - Cyclical industry, placing it in the top 54.7%.
Is Baijin Life Science Holdings' EBITDA Margin % too high?
Baijin Life Science Holdings' current EBITDA Margin % is 11.79%. The Retail - Cyclical industry median EBITDA Margin % is 7.48. Baijin Life Science Holdings' value of 11.79% is 57.7% above this industry median. Based on the distribution chart, Baijin Life Science Holdings ranks #617 out of 1128 companies in the Retail - Cyclical industry, which is below the industry midpoint. Overall, Baijin Life Science Holdings has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Baijin Life Science Holdings' EBITDA Margin % compare to TPR?
According to the Retail - Cyclical industry distribution chart, Baijin Life Science Holdings ranks #617 out of 1128 companies for EBITDA Margin %. This places Baijin Life Science Holdings in the lower half of its industry. The industry median EBITDA Margin % is 7.48. Baijin Life Science Holdings' value of 11.79% is 57.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Retail - Cyclical company?
The median EBITDA Margin % among Retail - Cyclical companies is 7.48, based on 1,128 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Baijin Life Science Holdings's current EBITDA Margin % of 11.79% is 57.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Baijin Life Science Holdings and its competitors. For the Retail - Cyclical industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Baijin Life Science Holdings's current EBITDA Margin % is 11.79%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Baijin Life Science Holdings stock overvalued right now?
Baijin Life Science Holdings (MNNGF) has a current EBITDA Margin % of 11.79%. The stock's GF Value™ is $0.04, compared to a current price of $0.08 — trading 87.5% above its estimated fair value. The current EBITDA Margin % is 11.79% and 57.7% above the Retail - Cyclical industry median of 7.48. Baijin Life Science Holdings' overall GF Score™ is 35/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Baijin Life Science Holdings (MNNGF), the current EBITDA Margin % is 11.79% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Baijin Life Science Holdings (MNNGF) Overvalued in 2026?
Based on GuruFocus' analysis, Baijin Life Science Holdings stock appears to be overvalued.
The current stock price of $0.08 is trading 87.5% above its estimated GF Value™ of $0.04.
Key valuation signals for MNNGF:
EBITDA Margin %: 11.79%
GF Value™: $0.04 vs. price of $0.08 (87.5% above fair value)
Industry Position: 57.7% above the Retail - Cyclical median (#617 of 1128)
No single metric tells the full story. See the MNNGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Baijin Life Science Holdings Ltd is positioned as a biopharmaceutical company dedicated in anti-aging and preventive medicine, as well as cellular precision therapy. The company has three business segment: jewelry business segment; strategic investment segment; and skincare business segment. The majority of revenue is coming from jewelry business segment.
35GF Score
Get the complete analysis for MNNGF
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MNNGF has been successfully added to your 
